Our study provides new insights into HNSCC immunotherapy by investigating the prognostic role of HtrAs in HNSCC and identifies HtrA3 as a potential prognostic marker and promising therapeutic target for HNSCC. The gene discussed is HTRA3; the disease is head and neck squamous cell carcinoma.